Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease
American Journal of Hypertension · 2025
DOI: 10.1093/ajh/hpaf028 ↗Kurz gefasst
Klinische Studie in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Sho Kinguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND We investigated the effects of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), on 24-hour blood pressure (BP) and safety for 12 weeks in Japanese patients with non-dialysis advanced chronic kidney disease (CKD). METHODS We conducted a prospective, single-arm exploratory study. Patients with non-dialysis CKD stage G4-5 (estimated glomerular filtration (eGFR) <30 mL/min/1.73 m2) who did not achieve their BP goals with angiotensin receptor blocker (ARB) administration, were enrolled and switched to sacubitril/valsartan. Primary and key secondary endpoints were changes from baseline in the 24-hour systolic BP (SBP) measured via ambulatory BP monitoring (ABPM) over 12 weeks and the safety, especially incidence of serum creatinine (Cr) increase (≥ 30% increase from baseline) and hyperkalemia. RESULTS Thirty patients were enrolled, and 29 patients were switched to sacubitril/valsartan. Efficacy analysis was conducted on 26 patients. Baseline mean eGFR and office BP were 21.1 ± 5.0 mL/min/1.73m2 and 149.4 ± 23.7/80.7 ± 11.9 mmHg, respectively. Baseline 24-hour, daytime, and nighttime BP were 139.6 ± 17.7/77.0 ± 7.8 mmHg, 143.5 ± 18.5/79.6 ± 8.7 mmHg, and 131.0 ± 20.4/71.1 ± 8.8 mmHg, respectively. After 12 weeks, changes in 24-hour, daytime, and nighttime SBP from baseline were -7.1 ± 12.4 mmHg (P < 0.01), -7.7 ± 12.9 mmHg (P < 0.01), and -5.8 ± 15.8 mmHg (P = 0.07), respectively. No incidences of potassium values > 6.0 mmol/L or serum Cr ≥ 30% increase from baseline were reported after sacubitril/valsartan initiation. CONCLUSIONS Switching from ARB to sacubitril/valsartan can safely enhance 24-hour antihypertensive treatment in patients with non-dialysis CKD G4-5 who do not achieve BP goals with ARBs. CLINICAL TRIALS REGISTRATION: Trial Number jRCT1031220149. CLINICAL TRIALS REGISTRATION Trial Number jRCT1031220149.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Nephrology and Hypertension, Yokohama City University Center Hospital, Yokohama, Japan.
- YCU Co-Creation Innovation Center, Yokohama City University, Yokohama, Japan.
- YCU Center for Novel and Exploratory Clinical Trials (Y-NEXT), Yokohama City University Hospital, Yokohama, Japan.
ORCID-Profile: Kouichi Tamura
Zitieren
APA
Kinguchi, S., Ishiga, K., Wakui, H., Azushima, K., Kanaoka, T., Kobayashi, Y., Haze, T., Hirawa, N., & Tamura, K. (2025). Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf028
Vancouver
Kinguchi S, Ishiga K, Wakui H, Azushima K, Kanaoka T, Kobayashi Y, et al. Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpaf028
BibTeX
@article{Kinguchi2025,
author = {Kinguchi, Sho and Ishiga, Kohei and Wakui, Hiromichi and Azushima, Kengo and Kanaoka, Tomohiko and Kobayashi, Yusuke and Haze, Tatsuya and Hirawa, Nobuhito and Tamura, Kouichi},
title = {Switching From ARBs to Sacubitril/Valsartan Safely Improves 24-Hour Ambulatory Blood Pressure in Patients With Advanced Chronic Kidney Disease},
journal = {American Journal of Hypertension},
year = {2025},
doi = {10.1093/ajh/hpaf028}
}
EUVIMED